Skip to Content
Health Policy Positions and Documents
- Clinical Pathways: Recommendations for Putting Patients at the Center of Value-Based Care (June 26, 2017)
- The Impact of Alternative Payment Models on Oncology Innovation and Patient Care (April 17, 2016).
- Recommendations to OHRP Regarding Human Subjects Research on Standard of Care Interventions (Sept. 9, 2013)
- Comments Regarding Senate “Reboot” Report on The Meaningful Use Incentive Program (May 28, 2013)
- Comments to ONC HIT Policy Committee Regarding Proposed Meaningful Use Stage 3 Criteria(Jan. 14, 2013)
- Comments Regarding the Patient-Centered Outcomes Research Institute’s Draft Methodology Report (Sept. 14, 2012)
- Comments to CMS Regarding Draft Stage 2 Meaningful Use Criteria (May 7, 2012)
- Meaningful Use Stage 2 RFC
- Comments Regarding the Patient-Centered Outcomes Research Institute’s Draft National Priorities and Research Agenda (March 15, 2012)
- Comments to CMS in Response to Proposed Update of Coverage with Evidence Development (CED) Guidance (Jan. 20, 2012)
- Coverage with Evidence Development
- Cancer Coalition Recommendations to CMS on Clinical Trials Coverage Regulations (Jan. 18, 2012)
- AACR, ASCO, AACI Comments in Response to HHS Advance Notice of Proposed Rulemaking (ANPRM), “Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay and Ambiguity for Investigators” (Oct. 26, 2011)
- Letter to CMS Requesting Clarity in Medicare Advantage Coverage of Cancer Clinical Trials